Search PubMed⌕ Search

Biomedical subjects

S Perlberg

Publications and source records attributed to S Perlberg.

26 records · Page 2Linked to original sources
PubMed1982

A method for discrimination between calcium oxalate kidney stone formers and normals.

Calcium ion concentration versus time was measured in solutions containing admixture of 10 per cent tested urine of normals and stone-formers, during induced calcium oxalate precipitation. A Discriminating Index was formulated by statistical analysis of the data. It was found that stone-formers and normals differ significantly with respect to the measurements and the Discriminating Indices. An equation to evaluate the odds of stone-forming based on results of an individual test has been derived. The Discrimination Index may be recommended as a diagnostic tool.

Adolescent↗
PubMed1981

Phenoxybenzamine for benign prostatic obstruction. Review of 200 cases.

Two hundred patients treated with phenoxybenzamine for benign prostatic obstruction were reviewed. In 171 of these patients the treatment was given to relieve symptoms in patients not requiring operation, or in patients in whom operation was postponed. Eighty per cent of these patients derived benefit from the treatment, most commonly for the obstructive symptoms (78.7 per cent) but almost as often for nocturia (76 per cent). The treatment was also found to be useful in aiding catheter removal after an attack of acute retention, and in preventing recurrent attacks of acute retention. Side effects occurred in 30 per cent of patients, but necessitated cessation of treatment in only 10 per cent. They consisted of other alpha-blocking effects, and caused after stopping or reducing treatment.

Adult↗
PubMed1978

A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction.

A double-blind placebo-controlled study of phenoxybenzamine for the symptomatic treatment of benign prostatic obstruction is reported. Statistically significant evidence of an improvement in both the peak and mean flow-rates was found. Both diurnal and nocturnal frequency were significantly diminished. Residual urine was unaffected, and the possible reasons for this are discussed. Urethral pressure recordings confirmed the reduction in the closure pressure in the prostatic segment of the urethra. It was concluded that there was good evidence that the treatment is effective.

Clinical Trials as Topic↗
PubMed1977

Dynamics of acute retention in prostatic patient and role of adrenergic receptors.

The dynamic changes in the lower urinary tract associated with acute retention in the prostatic patient were investigated by pressure studies. These revealed that the site of maximal urethral pressure was in the prostatic segment, the bladder neck was not tightly closed, and the normal tone of the external sphincter was inhibited. Bladder decompression altered these findings, and alpha-adrenergic blockade produced a reduction in all pressure parameters in the posterior urethra. The significance of the findings is discussed in relation to present-day knowledge of lower tract urodynamics. It is concluded that certain cases of acute retention in the prostatic patient may be initiated by stimulation of the prostatic alpha-adrenergic receptors, and may then be perpetuated by a secondary fall in intravesical pressure together with a supplementaty "feed-back" stimulation of these receptors due to the bladder overdistention itself. Decompression and/or alpha-adrenergic block may sometimes reverse this process.

Biomechanical Phenomena↗
PubMed1976

The use of alpha-adrenergic blockers in benign prostatic obstruction.

As a result of previous in-vitro studies on the alpha-adrenergic receptor activity of the human prostate and prostatic capsule a trial was made of alpha-adrenergic blockers for the relief of obstructive prostatic symptoms. Considerable benefit was obtained in several groups of patients, as demonstrated either by the relief or prevention of complete retention, or by diminution in residual urine or improvement in urinary flow-rate recordings. A number of illustrative cases are described, and the indications for the use of this treatment are suggested. It is emphasised that this treatment provides symptomatic relief only, and in no sense purports to be a treatment of the enlarged prostate itself.

Aged↗
PubMed1975

The treatment of benign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study.

A double-blind, placebo-controlled study using the antiandrogen compound flutamide in 30 patients with benign enlargement of the prostate is reported. The potency of the compound was indicated by the large percentage of patients suffering from gynecomastia or nipple pain. Flow rate recordings are probably the most reliable and useful examination in this type of investigation, and statistical analysis of the results showed evidence of significant improvement in patients receiving flutamide. No evidence of an effect as compared to the placebo was found when the residual urine, prostate size or histological changes in prostatic biopsies were examined. Subjective effects, when carefully analyzed, provided some evidence of a preference for the flutamide group, especially in the early weeks of treatment, but the fallaciousness of subjective observations is stressed. The various problems associated with the choice and measurement of parameters to be used in this type of investigation are discussed, and the absolute necessity of proper controls and statistical analysis in such a clinical study is illustrated.

Anilides↗